New 76-week Data: Upadacitinib Drives Sustained Repigmentation in Non-segmental Vitiligo

Upadacitinib (Rinvoq AbbVie) produces continued facial and total body repigmentation through Week 76 in patients with non-segmental vitiligo, according to new data from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies.